GLP-2 (Glucagon-Like Peptide-2)

# GLP-2 (Glucagon-Like Peptide-2): The Intestinotrophic Hormone Driving Gut Regeneration, Barrier Function, and Metabolic Research

Glucagon-like peptide-2 (GLP-2) is a 33-amino acid peptide hormone derived from posttranslational processing of the proglucagon gene (GCG). While its sibling peptide GLP-1 has captured enormous research attention for its role in glucose homeostasis and appetite regulation, GLP-2 occupies a distinct and equally fascinating biological niche: it is the most potent known endogenous intestinotrophic factor, capable of stimulating intestinal epithelial proliferation, enhancing nutrient absorption, strengthening gut barrier integrity, and modulating mesenteric blood flow. Its discovery in 1996 opened an entirely new chapter in gastrointestinal biology, and the development of DPP-IV-resistant analogs has transformed it into one of the most actively studied peptides in gut regeneration research.

For dosing, reconstitution, and protocol details, see our GLP-2 Dosage Protocol Guide: Gut Repair Research (2026).

This guide examines the molecular biology of GLP-2, its receptor pharmacology, downstream signaling cascades, roles in barrier function and bone metabolism, and the landscape of next-generation analogs currently under investigation.

---

Molecular Biology and Biosynthesis

Proglucagon Processing: The GLP-2 Origin Story

GLP-2 is encoded within the proglucagon gene (GCG), the same gene that produces glucagon, GLP-1, oxyntomodulin, glicentin, and several other bioactive peptides. The tissue-specific processing of proglucagon is governed by prohormone convertases (PCs): PC2 predominates in pancreatic alpha cells (yielding glucagon), while PC1/3 predominates in intestinal enteroendocrine L-cells and certain brainstem neurons (yielding GLP-1, GLP-2, oxyntomodulin, and glicentin).

GLP-2 corresponds to amino acids 126–158 of proglucagon. It is co-secreted with GLP-1 in an equimolar ratio from L-cells in response to nutrient ingestion, particularly luminal carbohydrates, fats, and short-chain fatty acids (Drucker, ACS Pharmacol Transl Sci, 2019).

Amino Acid Sequence and Structure

Human GLP-2 is a 33-amino acid peptide with the sequence:

H–A–D–G–S–F–S–D–E–M–N–T–I–L–D–N–L–A–A–R–D–F–I–N–W–L–I–Q–T–K–I–T–D–OH

The peptide adopts a predominantly alpha-helical conformation, particularly in the central and C-terminal regions. The N-terminal alanine at position 2 is critical: it serves as the cleavage site for dipeptidyl peptidase-IV (DPP-IV), which rapidly inactivates circulating GLP-2 by removing the N-terminal His-Ala dipeptide to generate the inactive metabolite GLP-2(3–33).

Secretion and Regulation

GLP-2 is secreted in a biphasic pattern following meal ingestion. The early phase (15–30 minutes) is likely mediated by neural and paracrine signals, while the later phase (60–120 minutes) corresponds to direct nutrient contact with L-cells in the distal ileum and colon. Peak circulating concentrations of GLP-2 reach approximately 15–40 pM in the postprandial state.

Key secretagogues include:

•Glucose and fructose — direct stimulation of L-cell nutrient sensors
•Long-chain fatty acids — via GPR120 and GPR40 signaling
•Short-chain fatty acids (SCFAs) — butyrate, propionate, and acetate from microbial fermentation
•Bile acids — via TGR5 (GPBAR1) on L-cells

This nutrient-responsive secretion pattern positions GLP-2 as a critical feed-forward signal: when nutrients arrive in the gut, GLP-2 primes the intestinal epithelium for enhanced absorption.

---

The GLP-2 Receptor (GLP-2R)

Discovery and Cloning

The GLP-2 receptor was cloned in 1999 by Munroe, Drucker, and colleagues at Allelix Biopharmaceuticals. It is a class B (secretin family) G protein-coupled receptor (GPCR) with 550 amino acids, encoded by the GLP2R gene on human chromosome 17p13.3 (Munroe et al., Proc Natl Acad Sci USA, 1999).

The GLP-2R shares significant sequence homology with the GLP-1 receptor (~50%) and the glucagon receptor (~47%), reflecting their common evolutionary origin within the secretin receptor family. However, GLP-2 does not activate the GLP-1R or glucagon receptor at physiological concentrations, and vice versa — demonstrating exquisite ligand selectivity within this receptor subfamily.

Tissue Distribution

The GLP-2R exhibits a remarkably restricted tissue distribution compared to other growth factor receptors, a feature that has important implications for selectivity and potential side effect profiles. Expression has been identified in:

•Gastrointestinal tract — stomach, duodenum, jejunum, ileum, colon (highest expression)
•Enteric nervous system — subepithelial myofibroblasts and enteric neurons
•Central nervous system — hypothalamus and brainstem (dorsomedial hypothalamus, nucleus of the solitary tract)
•Lung — low-level expression

Notably, a critical insight emerged from immunohistochemical studies: the GLP-2R is not expressed on intestinal epithelial cells themselves. Instead, it localizes to enteric neurons and subepithelial myofibroblasts (ISEMFs) in the intestinal lamina propria (Yusta et al., Gastroenterology, 2000). This means GLP-2 acts on the epithelium indirectly through paracrine intermediaries — a mechanism that took years to unravel.

Signal Transduction

GLP-2R activation triggers canonical class B GPCR signaling:

1. Gαs-cAMP-PKA pathway — The primary signaling cascade. GLP-2 binding activates adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A (PKA) and downstream transcription factors including CREB.

2. β-arrestin recruitment — GLP-2R also signals through β-arrestin-dependent pathways, potentially mediating receptor internalization and sustained signaling from endosomes.

3. Wnt/β-catenin cross-talk — GLP-2R signaling has been shown to intersect with Wnt pathway components in intestinal stem cells, though the precise mechanisms remain under investigation.

---

Downstream Mediators: The Indirect Trophic Network

Perhaps the most intellectually fascinating aspect of GLP-2 biology is that its intestinotrophic effects are not direct. Because the GLP-2R resides on stromal and neural cells rather than epithelial cells, GLP-2 must recruit a network of paracrine growth factors to exert its proliferative effects on the crypt-villus axis.

IGF-1: The Essential Mediator

Insulin-like growth factor-1 (IGF-1) was identified as a critical downstream effector of GLP-2 action by Dubé and Brubaker in 2006. Using IGF-1 knockout models, they demonstrated that GLP-2 enhances intestinal IGF-1 expression and secretion from subepithelial myofibroblasts, and that IGF-1 is required for both small and large intestinal growth in response to GLP-2 (Dubé et al., Gastroenterology, 2006).

The GLP-2 → IGF-1R signaling axis is now understood as:

1. GLP-2 binds GLP-2R on ISEMFs

2. cAMP/PKA signaling upregulates IGF-1 transcription and secretion

3. IGF-1 acts on epithelial IGF-1 receptors in crypts

4. Activation of PI3K/Akt and MAPK/ERK pathways drives crypt cell proliferation

EGF and KGF

Epidermal growth factor (EGF) synergistically enhances the proliferative actions of IGF-1 in intestinal crypt cells. The ErbB receptor network (EGF receptor family) has been implicated as a co-mediator of GLP-2-driven proliferation. Additionally, keratinocyte growth factor (KGF/FGF-7) is upregulated by GLP-2 in murine models, contributing to epithelial repair.

Nitric Oxide and Vasoactive Mediators

GLP-2 acutely increases mesenteric blood flow by 30–50% through a nitric oxide (NO)-dependent mechanism. Studies in neonatal piglet models demonstrated that GLP-2 increases intestinal endothelial nitric oxide synthase (eNOS) protein abundance and constitutive NOS activity (Guan et al., Gastroenterology, 2003). The GLP-2R co-localizes with eNOS-expressing and VIP-positive enteric neurons, suggesting that the vasodilatory response is neurally mediated.

This enhanced blood flow is not merely a consequence of increased metabolic demand — it appears to be a direct physiological action of GLP-2 that facilitates nutrient absorption and supports the metabolic demands of a rapidly proliferating epithelium.

---

Key Biological Actions in Research Models

Intestinal Growth and Mucosal Expansion

The original discovery of GLP-2's intestinotrophic activity by Drucker et al. in 1996 demonstrated that mice bearing proglucagon-producing tumors exhibited marked proliferation of the small intestinal epithelium. Administration of exogenous GLP-2 recapitulated this effect, increasing crypt cell proliferation, villus height, and overall mucosal mass (Drucker et al., Proc Natl Acad Sci USA, 1996).

Key findings from subsequent research include:

•Villus height increases of 40–100% in rodent models receiving exogenous GLP-2
•Selective trophic effects — small intestine > colon > stomach
•Crypt cell proliferation accompanied by reduced apoptosis, indicating GLP-2 promotes epithelial expansion through both mechanisms
•Prevention of intestinal atrophy during total parenteral nutrition (TPN)

Gut Barrier Function and Permeability

Beyond its growth-promoting effects, GLP-2 has emerged as a critical regulator of intestinal barrier integrity. Research has demonstrated that GLP-2:

•Enhances tight junction protein expression — upregulation of occludin, claudin-3, claudin-4, and ZO-1 in both in vitro and in vivo models (Moran et al., Regul Pept, 2012)
•Reduces paracellular permeability to macromolecules, including bacterial lipopolysaccharide (LPS)
•Attenuates TNFα-induced barrier disruption in Caco-2 intestinal cell monolayers
•Requires the intestinal epithelial IGF-1 receptor for its barrier-enhancing effects, connecting barrier function to the same paracrine network that drives proliferation

A landmark 2009 study by Cani et al. demonstrated that prebiotic-driven changes in gut microbiota increase endogenous GLP-2 production, which in turn improves gut barrier function and reduces metabolic endotoxemia in obese mouse models. This GLP-2-dependent mechanism directly linked the gut microbiome to systemic inflammation through barrier integrity (Cani et al., Gut, 2009).

Bone Metabolism

An unexpected dimension of GLP-2 research is its effect on bone resorption. Postprandial GLP-2 secretion contributes to the acute suppression of bone resorption markers (C-terminal telopeptide of type I collagen, CTX) that occurs after meals. Exogenous GLP-2 administration reduces serum CTX in a dose-dependent manner without significantly affecting bone formation markers, suggesting a selective anti-resorptive action (Gottschalck et al., Scand J Gastroenterol, 2008).

Intriguingly, this bone-protective effect requires an intact gastrointestinal tract — it is abolished in patients with jejunostomy. The mechanism likely involves indirect mediators released from the gut rather than direct GLP-2R activation on osteoclasts, as the GLP-2R has not been conclusively identified on bone cells.

Anti-Inflammatory and Cytoprotective Actions

GLP-2 demonstrates anti-inflammatory properties in multiple experimental paradigms:

•Reduced mucosal inflammation in experimental colitis models
•Decreased pro-inflammatory cytokine production (TNFα, IL-1β, IL-6)
•Protection against chemotherapy-induced mucositis through maintenance of epithelial integrity
•Modulation of intestinal immune cell populations, including effects on intraepithelial lymphocytes and lamina propria macrophages

---

DPP-IV Degradation and the Development of Resistant Analogs

The Half-Life Problem

Native GLP-2 has an extremely short circulating half-life of approximately 7 minutes in humans, severely limiting its utility as a research tool for chronic studies. This rapid degradation is primarily mediated by DPP-IV (also known as CD26), which cleaves the N-terminal His¹-Ala² dipeptide to generate the inactive (and potentially antagonistic) metabolite GLP-2(3–33).

Teduglutide: The First DPP-IV-Resistant Analog

The recognition that a simple Ala²→Gly² substitution could confer DPP-IV resistance while maintaining full agonist activity at the GLP-2R was a pivotal advance. This single amino acid change — replacing alanine with glycine at position 2 — extended the half-life from ~7 minutes to approximately 2 hours, sufficient for once-daily administration (Drucker, ACS Pharmacol Transl Sci, 2019).

Teduglutide ([Gly²]GLP-2) has been extensively characterized in preclinical models, demonstrating:

•Significant intestinotrophic activity with daily subcutaneous administration
•Enhanced mucosal adaptation in short bowel syndrome models
•Improved nutrient and fluid absorption
•Reduced pro-inflammatory cytokine levels in colitis models

Apraglutide: The Next-Generation Long-Acting Analog

Apraglutide represents a further evolution in GLP-2R agonist design. This synthetic analog incorporates four amino acid substitutions that confer:

•Complete DPP-IV resistance
•High plasma protein binding reducing renal clearance
•An elimination half-life of approximately 72 hours — enabling once-weekly administration
•Selectivity for GLP-2R confirmed across a panel of 80 receptors, ion channels, and transporters

Phase 1/2 studies have demonstrated that once-weekly apraglutide significantly improves intestinal fluid and energy absorption in short bowel syndrome models, with a favorable tolerability profile (Eliasson et al., JPEN, 2022).

GLP-1/GLP-2 Dual Agonists

One of the most exciting frontiers in proglucagon peptide research is the development of chimeric GLP-1/GLP-2 dual agonists. The rationale is compelling: GLP-1 reduces food intake and improves glucose homeostasis, while GLP-2 strengthens gut barrier function and reduces metabolic endotoxemia. In diet-induced obese mouse models, GLP-1/GLP-2 co-agonists demonstrate greater glycemic and intestinotrophic effects than GLP-1 receptor agonist monotherapy.

This dual-agonist approach is particularly relevant in the context of obesity research, where the 'leaky gut' hypothesis posits that impaired barrier function allows bacterial LPS translocation, driving chronic low-grade inflammation that exacerbates insulin resistance (Targeting the GLP-2 receptor in the management of obesity, 2024).

---

GLP-2 in the Context of the Proglucagon Family

Understanding GLP-2 requires situating it within the broader proglucagon peptide family:

Peptide	Primary Receptor	Key Research Areas
Glucagon	GCGR	Glycogenolysis, gluconeogenesis, energy mobilization
GLP-1	GLP-1R	Glucose homeostasis, appetite, cardiovascular
GLP-2	GLP-2R	Intestinal growth, barrier function, nutrient absorption
Oxyntomodulin	GLP-1R / GCGR	Dual agonism, metabolic research
Glicentin	Unknown	Intestinal growth (less potent than GLP-2)
GIP	GIPR	Incretin signaling, dual/triple agonist research

GLP-2 and GLP-1 are co-secreted from the same L-cells in equimolar ratios, creating a coordinated postprandial response: GLP-1 potentiates insulin secretion and slows gastric emptying, while GLP-2 enhances intestinal absorptive capacity and barrier integrity. This coordinated release is not coincidental — it represents an evolved mechanism for optimizing nutrient assimilation.

---

Research Methodology Considerations

Handling and Preparation

GLP-2 and its analogs require careful handling for in vitro and in vivo research:

•Reconstitution — dissolve in sterile water or PBS at neutral pH; avoid acidic conditions that may promote aggregation
•Storage — lyophilized peptide at −20°C to −80°C; reconstituted aliquots at −80°C; avoid repeated freeze-thaw cycles
•DPP-IV inhibitors — when studying native GLP-2 in vitro, consider adding DPP-IV inhibitors (e.g., diprotin A, sitagliptin) to prevent rapid degradation
•Carrier protein — low-concentration solutions benefit from BSA or similar carrier protein to prevent adsorptive losses

Common Research Models

•Short bowel resection models (rodent, porcine) — the gold standard for intestinotrophic activity
•TPN models — total parenteral nutrition-induced atrophy as a readout for GLP-2R agonist efficacy
•DSS colitis models — dextran sodium sulfate-induced colitis for anti-inflammatory assessment
•Caco-2 monolayers — in vitro barrier function studies using transepithelial electrical resistance (TEER)
•Ussing chamber preparations — ex vivo intestinal permeability measurements
•Diet-induced obesity models — for barrier function and metabolic endotoxemia studies

Quantification Methods

•Radioimmunoassay (RIA) and ELISA for circulating GLP-2 levels (note: must distinguish intact GLP-2(1–33) from DPP-IV-cleaved GLP-2(3–33))
•Morphometric analysis — villus height, crypt depth, muscularis thickness
•BrdU/Ki-67 immunohistochemistry — crypt cell proliferation indices
•TUNEL staining — apoptosis quantification
•TEER measurements — in vitro barrier function
•FITC-dextran permeability — in vivo barrier function assessment

---

Current Research Frontiers

Gut-Brain Axis

GLP-2R expression in the hypothalamus and brainstem suggests central actions that remain poorly characterized. Preliminary research indicates roles in:

•Modulation of food intake (though effects are modest compared to GLP-1)
•Regulation of hepatic glucose production through a gut-brain-liver neural axis
•Potential neuroprotective effects, though evidence is nascent compared to the extensive neuroprotection literature for GLP-1 agonists

Microbiome Interactions

The relationship between GLP-2 and the gut microbiome is bidirectional:

•Microbiome → GLP-2: Microbial fermentation products (SCFAs) stimulate GLP-2 secretion from L-cells
•GLP-2 → Microbiome: GLP-2-driven improvements in barrier function alter the luminal environment, potentially reshaping microbial composition

This bidirectional loop has implications for understanding how dietary fiber, prebiotics, and probiotics influence gut health through endogenous incretin hormone production.

Chemotherapy-Induced Mucositis

GLP-2R agonists are being investigated as potential protective agents against chemotherapy-induced gastrointestinal mucositis. Preclinical data with apraglutide demonstrate enhanced intestinal protection and survival after cytotoxic chemotherapy in mouse models, suggesting that GLP-2R agonism could preserve gut integrity during cytotoxic treatment protocols.

Graft-Versus-Host Disease (GvHD)

The gut is a primary target organ in acute graft-versus-host disease following allogeneic transplantation. GLP-2R agonists are being explored for their ability to maintain epithelial barrier integrity and reduce gastrointestinal GvHD severity through enhanced mucosal repair.

---

Several other peptides and growth factors exhibit intestinotrophic activity, but GLP-2 is distinguished by its restricted receptor distribution and physiological regulation:

•EGF — potent mitogen but broadly expressed receptor; less gut-selective
•IGF-1 — operates downstream of GLP-2 but also has systemic metabolic effects via ubiquitous IGF-1R expression
•KGF (FGF-7) — stimulates epithelial proliferation but primarily in injury contexts
•GHK-Cu — operates through gene expression modulation rather than receptor-mediated trophic signaling
•BPC-157 — different mechanism (proposed NO system, FAK-paxillin) with broader tissue targets

GLP-2's advantage as a research tool lies in its endogenous, nutrient-regulated, and receptor-specific nature — making it ideal for investigating physiological mechanisms of intestinal adaptation.

---

Summary

GLP-2 represents a cornerstone of intestinal biology research. From its discovery as a 'peptide without a function' in 1996 to its current status as the most potent known endogenous intestinotrophic hormone, GLP-2 has illuminated fundamental mechanisms of gut epithelial renewal, barrier maintenance, and nutrient absorption. The development of DPP-IV-resistant analogs — from the first-generation Gly² substitution to the long-acting apraglutide — exemplifies rational peptide engineering driven by mechanistic understanding.

Current research frontiers, including GLP-1/GLP-2 dual agonism, microbiome-GLP-2 interactions, and chemotherapy/GvHD mucosal protection, position GLP-2R pharmacology at the intersection of gastroenterology, metabolic science, and oncology. For researchers investigating intestinal physiology, barrier biology, or the gut-systemic inflammation axis, GLP-2 remains an indispensable tool.

---

Research Tools

Researchers sourcing this peptide for laboratory investigation can use the peptide price comparison tool to identify research-grade material from verified suppliers. For reconstitution planning, the peptide calculator provides molar mass, concentration, and dilution calculations.

References

1. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93(15):7911-7916. PubMed

2. Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 1999;96(4):1569-1573. PubMed

3. Drucker DJ. The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome. ACS Pharmacol Transl Sci. 2019;3(1):3-15. PubMed

4. Dubé PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology. 2006;131(2):589-605. PubMed

5. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091-1103. PubMed

6. Moran GW, O'Neill C, McLaughlin JT. GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrier. Regul Pept. 2012;178(1-3):95-101. PubMed

7. Gottschalck IB, Jeppesen PB, Holst JJ, Henriksen DB. Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scand J Gastroenterol. 2008;43(8):929-937. PubMed

8. Guan X, Stoll B, Lu X, et al. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets. Gastroenterology. 2003;125(1):136-147. PubMed

9. Eliasson J, Hvistendahl MK, Freund N, et al. Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome. JPEN. 2022;46(7):1639-1649. PubMed

10. Wismann P, Pedersen SL, Hansen G, et al. Targeting the GLP-2 receptor in the management of obesity. Expert Opin Ther Targets. 2024. PubMed

---

Further Reading:

---

This article is intended for research and educational purposes only. GLP-2 and its analogs are research compounds under investigation. All references to biological activity describe findings from in vitro assays, animal models, or published research literature. No information herein constitutes guidance for non-research applications.